Abstract:Bullous pemphigoid (BP), the by far most frequent autoimmune subepidermal blistering disorder (AIBD), is characterized by the deposition of autoantibodies against BP180 (type XVII collagen; Col17) and BP230 as well as complement components at the dermal-epidermal junction (DEJ). The mechanisms of complement activation in BP patients, including the generation of C5a and regulation of its two cognate C5aRs, i.e., C5aR1 and C5aR2, are incompletely understood. In this study, transcriptome analysis of perilesional and non-lesional skin biopsies of BP patients compared to site-, age-, and sex-matched controls showed an upregulated expression of C5AR1, C5AR2, CR1, and C3AR1 and other complement-associated genes in perilesional BP skin. Of note, increased expressions of C5AR2 and C3AR1 were also observed in non-lesional BP skin. Subsequently, double immunofluorescence (IF) staining revealed T cells and macrophages as the dominant cellular sources of C5aR1 in early lesions of BP patients, while C5aR2 mainly expressed on mast cells and eosinophils. In addition, systemic levels of various complement factors and associated molecules were measured in BP patients and controls. Significantly higher plasma levels of C3a, CD55, and mannose-binding lectin-pathway activity were found in BP patients compared to controls. Finally, the functional relevance of C5aR1 and C5aR2 in BP was explored by two in vitro assays. Specific inhibition of C5aR1, resulted in significantly reduced migration of human neutrophils toward the chemoattractant C5a, whereas stimulation of C5aR2 showed no effect. In contrast, the selective targeting of C5aR1 and/or C5aR2 had no effect on the release of reactive oxygen species (ROS) from Col17-anti-Col17 IgG immune complex-stimulated human leukocytes. Collectively, this study delineates a complex landscape of activated complement receptors, complement factors, and related molecules in early BP skin lesions. Our results corroborate findings in mouse models of pemphigoid diseases that the C5a/C5aR1 axis is pivotal for attracting inflammatory cells to the skin and substantiate our understanding of the C5a/C5aR1 axis in human BP. The broad expression of C5aRs on multiple cell types critical for BP pathogenesis call for clinical studies targeting this axis in BP and other complement-mediated AIBDs.

Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis

Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid

Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity

020 Profile of BP180 and BP230-specific IgE Autoantibodies in Bullous Pemphigoid

Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230

IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients

848 Clinical and Immunological Profiles of BP-specific IgE Autoantibodies in Bullous Pemphigoid

Presence of immunoglobulin E‐expressing antibody‐secreting cells in the dermis close to bullous pemphigoid lesions

Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity

BP230 IgE Autoantibodies in Topical-Steroid-resistant Bullous Pemphigoid

[Erythroderma with immunoglobulin deposits along the basal membrane. Pemphigoid erythroderma?]

Identification of the target antigen in chronic bullous disease of childhood and linear IgA disease of adults

050 Eotaxin-1 and Matrix Metalloproteinase-9 Are Critical in Anti-Bp180 IgE-induced Experimental Bullous Pemphigoid

Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients

IgE anti-BP180 NC16A autoantibody in both serum and blister fluid samples does not correlate with disease activity of bullous pemphigoid

Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing

Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation

IgG autoantibodies in bullous pemphigoid directly induce a pathogenic MyD88-dependent pro-inflammatory response in keratinocytes:

Normal Human Skin Is Superior To Monkey Oesophagus Substrate For Detection Of Circulating Bp180-Nc16a-Specific Igg Antibodies In Bullous Pemphigoid

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid